Mechanism of action
Vivecon targets the gag polyprotein precursor, the main structural protein responsible for assembly and budding of virion particles. By binding to the gag polyprotein, vivecon prevents its cleavage by the protease enzyme into functional subunits. Unlike the protease inhibitors, vivecon binds the gag protein, not the protease enzyme. The resulting virus particles are structurally defective and are incapable of spreading infection through the body.
- ↑ Myriad Genetics Submits IND on Vivecon for the treatment of AIDS. Retrieved on 2008-01-28.
|Antiviral drugs: antiretroviral drugs used against HIV (primarily J05)|
|Entry/fusion inhibitors </br> (Discovery & development)|
|Protease Inhibitors (PI)</br>(Discovery and development)||
|This antiinfective drug article could benefit from further information. You can help us by expanding it.|
| This article uses material from the Wikipedia article Vivecon, that was deleted or is being discussed for deletion, which is released under the Creative Commons Attribution-ShareAlike 3.0 Unported License.